1.	Low-dose Temozolomide for 2 Weeks on Brain Tumor (Study P04602AM1) Phase: Phase IV Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: P04602, NCT00424554
2.	Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Phase: Phase III, Phase II Type: Treatment Status: Active Age: 0 to 30 Sponsor: Other Protocol IDs: EUDRACT 2005-002618-40, BfArM-4030755, EC-105/05, DKS 2006.01, NCT00749723
3.	Phase III Randomized Study of Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Patients With Recurrent Malignant Glioma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MRC-BR12, EU-20114, ISRCTN83176944, NCT00052455
4.	Phase III Randomized Study of Radiotherapy Versus Temozolomide in Patients With Low-Grade Gliomas Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EORTC-22033, EORTC-26033, EudraCT-2004-002714-11, CAN-NCIC-CE5, NCT00182819, TROG 06.01, CE5
5.	Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TASMC-05-FB-05235-CTIL, NCT00268684
6.	Phase III Pilot Study of Induction Chemotherapy Followed by Consolidation Myeloablative Chemotherapy Comprising Thiotepa and Carboplatin With or Without Etoposide and Autologous Hematopoietic Stem Cell Rescue in Pediatric Patients With Previously Untreated Malignant Brain Tumors Phase: Phase III Type: Treatment Status: Active Age: Under 10 at diagnosis Sponsor: Other Protocol IDs: CHLA-HEAD-START-III, CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06
7.	A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LX01-315, NCT00395070
8.	Phase III Randomized Study of Short-Course Radiotherapy With or Without Temozolomide in Older Patients With Newly Diagnosed Glioblastoma Multiforme Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 65 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CAN-NCIC-CE6, EORTC-26062, EORTC-22061, CE6, SPRI-CAN-NCIC-CE.6, NCT00482677
9.	Phase III Randomized Study of Radiotherapy With or Without Concurrent and/or Adjuvant Temozolomide in Patients With Non-1p/19q Deleted Anaplastic Glioma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EORTC-26053, RTOG-0834, EORTC-22054, EUDRACT-2006-001533-17, SPRI-EORTC-26053, NCT00626990
10.	Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: EMD 121974-011, EORTC 26071-22072, NCT00689221
11.	Nimotuzumab in Adults With Glioblastoma Multiforma Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: OSAG101-BSA05, NCT00753246
12.	Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: AP 12009-G005, NCT00761280
13.	Phase III Randomized Study of Standard Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Older Patients With Glioblastoma Multiforme Phase: Phase III Type: Treatment Status: Active Age: 60 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: LEONB-ET2005-006, ET2005-006, LEONB-Nordic Glioma Adulte, INCA-RECF0031, EUDRACT-2006-003606-25, SPRI-LEONB-ET2005-006, NCT00820963
14.	Phase III Randomized Study of Concurrent Chemoradiotherapy and Adjuvant Temozolomide With Versus Without Bevacizumab in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0825, RTOG 0825, NCT00884741
15.	Phase III Randomized Study of Radiotherapy Alone Versus Radiotherapy With Concurrent and Adjuvant Temozolomide Versus Temozolomide Alone in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Glioma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0577, N0577, NCT00887146
16.	Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: IcmLCBT_301, NCT00807027
17.	Treatment Strategy for Low-Grade Gliomas Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: YP2008009, NCT00897377
18.	Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EF-14, NCT00916409
19.	A Study of Avastin (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO21990, 2008-006146-26, NCT00943826
20.	Phase III Randomized Study of Radiotherapy With Versus Without Temozolomide in Patients With Symptomatic or Progressive Low-Grade Gliomas Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E3F05, E3F05, NCT00978458
21.	Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors Phase: Phase III Type: Tissue collection/Repository, Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: 2009-0232, NCT01014767
22.	Phase I/II Study of Chemotherapy Comprising Methotrexate, Rituximab, and Temozolomide Before Radiotherapy and Temozolomide After Radiotherapy in Patients With Primary Central Nervous System Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0227, NCT00068250
23.	PS-341 With Oral Temozolomide in Patients With Advanced Refractory Solid Tumors or Melanoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2333, PHI 0241, NCT00209248
24.	Phase I/II Study of High-Dose Calcitriol and Temozolomide in Patients With Metastatic Melanoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: NU-05M1, NU-0310-093, SPRI-NU-05M1, NCT00301067
25.	Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: Eudract-2005-003911-63, PEI 119/01, NCT00311857